登录 注册 会员服务 联系我们

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

  • Published:2014-10 Issue:10 Volume:25 Page:1988-1995
  • ISSN:0923-7534
  • Container-title:Annals of Oncology
  • language:en
  • Short-container-title:Annals of Oncology

Author:

McNeish I.A.,Ledermann J.A.,Webber L.,James L.,Kaye S.B.,Hall M.,Hall G.,Clamp A.,Earl H.,Banerjee S.,Kristeleit R.,Raja F.,Feeney A.,Lawrence C.,Dawson-Athey L.,Persic M.,Khan I.

Funder

Cancer Research UK

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference25 articles.

1. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer;Markman;J Clin Oncol,2002

2. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients;Kaern;Eur J Gynaecol Oncol,2002

3. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer;Ghamande;Int J Gynecol Cancer,2003

4. Src family kinases and paclitaxel sensitivity;Le;Cancer Biol Ther,2011

5. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors;Alvarez;Cancer,2006

Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3